Payers as gatekeepers: how insurers and health systems decide what actually sells, MBA Training, MBA Training
4/5+150 XP
Payers as gatekeepers: how insurers and health systems decide what actually sells
# Payers as gatekeepers: how insurers and health systems decide what actually sells
In 2015, Gilead's hepatitis C cure Sovaldi hit US pharmacies with a list price of $84,000 for a 12 week course. The drug was clinically extraordinary: cure rates above 90%. But insurers panicked, state Medicaid programs (US government health coverage for low income residents) rationed it to only the sickest patients, and it took years of formulary fights before access broadened. The lesson stuck with the whole industry: a great drug means nothing if the people who pay for it say no.
That's the subject of this lesson. Payers, not regulators, are often the real gatekeepers of commercial success.
Who counts as a "payer"
A payer is whoever actually foots the bill for a medicine, distinct from the patient who takes it and the regulator who approves it.
In the US: private insurers (UnitedHealthcare, CVS Health/Aetna, Cigna), employer-sponsored plans, and government programs (Medicare for seniors, Medicaid for low income populations).
In the UK: the NHS (National Health Service, the UK's public health system), advised by NICE (National Institute for Health and Care Excellence, which evaluates whether treatments are cost-effective enough for NHS funding).
In Germany: statutory health insurers ("Krankenkassen"), guided by IQWiG (Institute for Quality and Efficiency in Health Care) assessments.
In most of Europe: single or dominant public payers with centralized negotiating power.
Regulators like the FDA (US Food and Drug Administration) or EMA (European Medicines Agency) answer one question: is this drug safe and effective enough to sell at all? Payers answer a different, often harsher question: is it worth what you're charging?
The US model: formularies as private-sector rationing
In the US, insurers and their PBMs (pharmacy benefit managers, companies like CVS Caremark, Express Scripts, and OptumRx that negotiate drug prices and manage formularies on behalf of insurers) build a "formulary": a tiered list of which drugs are covered, at what patient cost, and under what restrictions.
Manufacturers compete for favorable formulary placement much like consumer brands compete for supermarket shelf space. Mechanics include:
Rebates: manufacturers pay PBMs a rebate off list price in exchange for preferred tier placement. This is why US list prices are often far higher than what payers actually net, a well documented but hard to quantify gap since rebate terms are confidential.
Prior authorization: doctors must justify a prescription to the insurer before it's covered, a major source of prescribing friction.
Step therapy: patients must "fail first" on a cheaper drug before the insurer covers a pricier one.
This creates real competitive leverage. Three PBMs control an estimated 70 to 80% of US prescription volume (estimate, widely cited in industry and congressional analyses as of the mid-2020s). That concentration gives them significant pricing power over manufacturers, even ones with blockbuster drugs.
The UK model: NICE and explicit cost-effectiveness math
The UK takes a more transparent, centralized approach. NICE evaluates new drugs using a standardized metric: the QALY (quality-adjusted life year, a measure combining length and quality of life gained from treatment).
NICE's long-standing willingness-to-pay threshold has generally sat around £20,000 to £30,000 per QALY gained (published NICE methodology, figures can shift for specific disease areas such as end-of-life cancer treatments). If a drug's cost per QALY comes in above that range, NICE can simply say no, regardless of how well it works clinically.
Simple worked example:
Suppose Drug X costs £15,000 per patient per year and extends life by 1.5 quality-adjusted years compared to standard care.
Cost per QALY = £15,000 ÷ 1.5 = £10,000 per QALY
That comfortably clears NICE's threshold zone, likely leading to approval for NHS funding. Now suppose the same drug costs £60,000 per year for the same 1.5 QALY gain:
£60,000 ÷ 1.5 = £40,000 per QALY
That's above the typical threshold, putting NHS funding at real risk unless the manufacturer offers a confidential discount (common in practice) or the disease qualifies for a higher threshold exception.
This is why manufacturers frequently launch in the UK at a discount, or negotiate confidential "patient access schemes," to get under the line. NICE's rulings also ripple globally: many countries reference UK, German, or other advanced-market prices when setting their own, a practice called international reference pricing.
Payers reshape competitive dynamics in ways clinical trial data alone never could:
1. Second-to-market drugs can still win. If a "me-too" drug (a similar molecule targeting the same condition as an existing one) offers a modest efficacy edge but a much better cost-per-QALY or accepts a steeper rebate, it can out-compete a clinically superior rival for formulary placement.
2. Payer power varies by disease area. In rare diseases with no alternative treatment, payers have less leverage. In crowded categories, like diabetes or cholesterol drugs, payers can play manufacturers off each other for rebates.
3. Health system structure shapes launch strategy. Companies often sequence launches: pricing high in the less price-sensitive US market first, then negotiating down for UK, German, or other reference-pricing markets later.
4. Value-based contracts are emerging. Some payers now tie reimbursement to real-world outcomes: pay less if the drug underperforms in practice. This shifts commercial risk back onto manufacturers.
Knowledge check
1. What core distinction does the Sovaldi hepatitis C example illustrate about drug commercialization?
2. How does the fundamental question a payer asks differ from the question a regulator asks?
3. A company is planning market access strategy for a new drug in a country with a single dominant public payer (like the UK's NHS advised by NICE). What is the key strategic implication compared to the fragmented US payer landscape?
MULTIPLE CHOICE
4. Select ALL correct answers about who functions as a 'payer' in a given health system.
Select all the correct answers.
MULTIPLE CHOICE
5. Select ALL correct answers describing why payers are described as 'gatekeepers' of commercial success in the pharmaceutical industry.
Select all the correct answers.
The power balance: who really has veto power
It helps to rank leverage across the chain:
Payers/PBMs (US): high leverage on formulary placement and net price, especially for crowded drug classes.
NICE/HTA bodies (Europe): high leverage on market access and de facto global reference price.
Regulators (FDA/EMA): gatekeepers of legality, not economics. Approval doesn't guarantee reimbursement.
Manufacturers: retain leverage mainly through genuine innovation (first-in-class drugs, breakthrough therapies with no substitute) or scale (large firms can absorb rebate pressure that smaller biotechs cannot).
Patients/physicians: least structural power in this negotiation, despite being the intended "customer." Prescribing decisions are heavily constrained by what payers will actually cover.
This is why pharma executives increasingly say "payers are the new regulators." A drug can sail through FDA approval and still commercially fail if PBMs won't place it favorably or NICE rejects its price.
Key Takeaways
Payers (US insurers/PBMs, UK's NHS via NICE, and equivalents like Germany's IQWiG) determine commercial success independent of regulatory approval; getting a drug legally sellable is not the same as getting it reimbursed.
The US system relies on opaque, negotiated rebates and tiered formularies; PBM concentration (an estimated 70 to 80% of volume held by three players) gives payers major pricing leverage.
The UK's NICE uses an explicit, transparent metric (cost per QALY, roughly £20,000 to £30,000 threshold as a benchmark) that manufacturers must design pricing around, often accepting confidential discounts to clear the bar.
Payer decisions ripple internationally through reference pricing, meaning a rejection or discount in one major market can pressure prices elsewhere.
Competitive strategy in pharma increasingly means designing for payer economics from the start (health economics data, comparator trials, pricing sequencing), not just designing for clinical superiority.